{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:30:58Z","timestamp":1786516258611,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder caused by loss-of-function variants in the\n                      <jats:italic>NF1<\/jats:italic>\n                      gene. Segmental neurofibromatosis represents a rare mosaic form resulting from postzygotic mutations and is often diagnostically challenging due to its localized presentation and variable clinical expressivity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 25-year-old woman with neurofibromas restricted to the left facial region underwent histopathological evaluation and whole exome sequencing (WES) of lesional tissue. Bioinformatic analyses were used to predict the splicing impact of a novel intronic variant. A minigene splicing assay was performed to experimentally assess transcript-level consequences. Protein structural modeling was used to evaluate the predicted effects on neurofibromin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We describe a 25-year-old woman with a segmental distribution of neurofibromas confined to the left facial region, with a progressive mass present for more than two decades. Histopathological and immunohistochemical evaluation of the lesional tissue was performed, followed by WES of paired peripheral blood and affected tissue. WES of the affected tissue identified a novel somatic intronic deletion,\n                      <jats:italic>NF1<\/jats:italic>\n                      c.7970+4_7970+7del, with a mosaic variant allele fraction of 36.02%. In silico analyses predicted disruption of the canonical donor splice site. A minigene splicing assay experimentally confirmed that the variant causes complete exon 54 skipping, which is predicted to result in a frameshift and premature termination. These findings provide functional evidence that NF1 c.7970+4_7970+7del is a splice-disrupting variant with pathogenic relevance in the context of segmental neurofibromatosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This case expands the spectrum of splice-altering\n                      <jats:italic>NF1<\/jats:italic>\n                      variants and reveals a previously uncharacterized molecular mechanism underlying segmental neurofibromatosis. The mosaic nature of this somatic variant has important genetic counseling implications, including the possibility of low-level germline involvement. Our results highlight the value of functional validation for intronic variants of uncertain significance and support the potential role of early molecular diagnosis in guiding targeted therapeutic approaches such as MEK inhibition.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnins.2026.1887523","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:56:27Z","timestamp":1786514187000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A somatic NF1 splice-altering variant identified in lesional tissue in peripheral blood-negative segmental facial neurofibromatosis"],"prefix":"10.3389","volume":"20","author":[{"given":"Song","family":"Su","sequence":"first","affiliation":[{"name":"Neurology Department, Children's Hospital Affiliated to Shandong University","place":["Jinan, Shandong, China"]},{"name":"Neurology Department, Jinan Children\u2019s Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haochen","family":"Zou","sequence":"additional","affiliation":[{"name":"Pediatrics, Yanbian University Medical College","place":["Yanji, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhua","family":"Lin","sequence":"additional","affiliation":[{"name":"Pediatrics, Anqiu People's Hospital","place":["Weifang, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Neurology Department, WeiFang Maternal and Child Health Hospital","place":["Weifang, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ren","sequence":"additional","affiliation":[{"name":"Neurology Department, Children's Hospital Affiliated to Shandong University","place":["Jinan, Shandong, China"]},{"name":"Neurology Department, Jinan Children\u2019s Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Neurology Department, Children's Hospital Affiliated to Shandong University","place":["Jinan, Shandong, China"]},{"name":"Neurology Department, Jinan Children\u2019s Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wandong","family":"Hu","sequence":"additional","affiliation":[{"name":"Neurology Department, Children's Hospital Affiliated to Shandong University","place":["Jinan, Shandong, China"]},{"name":"Neurology Department, Jinan Children\u2019s Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyue","family":"Li","sequence":"additional","affiliation":[{"name":"Neurology Department, Children's Hospital Affiliated to Shandong University","place":["Jinan, Shandong, China"]},{"name":"Neurology Department, Jinan Children\u2019s Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Emergency department, Children\u2019s Hospital Affiliated to Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Neurology Department, Children's Hospital Affiliated to Shandong University","place":["Jinan, Shandong, China"]},{"name":"Neurology Department, Jinan Children\u2019s Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1177\/10600280211046298","article-title":"A review of selumetinib in the treatment of neurofibromatosis type 1-related plexiform neurofibromas","volume":"56","author":"Anderson","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s13353-018-0444-7","article-title":"Splicing mutations in human genetic disorders: examples, detection, and confirmation","volume":"59","author":"Anna","year":"2018","journal-title":"J. Appl. Genet."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12885-023-10996-y","article-title":"Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas","volume":"23","author":"Armstrong","year":"2023","journal-title":"BMC Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/hmg\/9.2.237","article-title":"Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1","volume":"9","author":"Ars","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.3390\/cells9112365","article-title":"Neurofibromin structure, functions and regulation","volume":"9","author":"Bergoug","year":"2020","journal-title":"Cells"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/s0092-8674(01)00245-8","article-title":"NF1 tumor suppressor gene function: narrowing the GAP","volume":"104","author":"Cichowski","year":"2001","journal-title":"Cell"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.0022-202X.2005.23834.x","article-title":"Gonosomal mosaicism for a nonsense mutation (R1947X) in the NF1 gene in segmental neurofibromatosis type 1","volume":"125","author":"Consoli","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of Selumetinib in Neurofibromatosis type 1-related plexiform Neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13023-021-01796-3","article-title":"Clinical features and disease severity in patients with mosaic neurofibromatosis type 1: a single-center study and literature review","volume":"16","author":"Ejerskov","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1086\/302809","article-title":"Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain","volume":"66","author":"Fahsold","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","article-title":"Management of neurofibromatosis type 1-associated plexiform neurofibromas","volume":"24","author":"Fisher","year":"2022","journal-title":"Neuro-Oncology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","article-title":"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial","volume":"27","author":"Fisher","year":"2021","journal-title":"Nat. Med."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10689-006-9001-3","article-title":"Molecular diagnosis of neurofibromatosis type 1: 2 years experience","volume":"6","author":"Griffiths","year":"2007","journal-title":"Fam. Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","article-title":"Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas","volume":"25","author":"Gross","year":"2023","journal-title":"Neuro-Oncology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/ng1194-218","article-title":"Screening for truncated NF1 proteins","volume":"8","author":"Heim","year":"1994","journal-title":"Nat. Genet."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/humu.20400","article-title":"Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution, and consequences for mRNA splicing","volume":"28","author":"Krawczak","year":"2007","journal-title":"Hum. Mutat."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev.pathol.2.010506.091940","article-title":"Neurofibromatosis","volume":"2","author":"Mcclatchey","year":"2007","journal-title":"Annu. Rev. Pathol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/1098-1004(200006)15:6<541::Aid-humu6>3.0.Co;2-n","article-title":"Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects","volume":"15","author":"Messiaen","year":"2000","journal-title":"Hum. Mutat."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1212\/wnl.58.10.1461","article-title":"Plexiform neurofibromas in NF1: toward biologic-based therapy","volume":"58","author":"Packer","year":"2002","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/oxfordjournals.aje.a010118","article-title":"NF1 gene and neurofibromatosis 1","volume":"151","author":"Rasmussen","year":"2000","journal-title":"Am. J. Epidemiol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1212\/wnl.56.11.1433","article-title":"The clinical and diagnostic implications of mosaicism in the neurofibromatoses","volume":"56","author":"Ruggieri","year":"2001","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1016\/j.febslet.2012.06.006","article-title":"Pleckstrin homology (PH) like domains - versatile modules in protein-protein interaction platforms","volume":"586","author":"Scheffzek","year":"2012","journal-title":"FEBS Lett."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.5114\/pdia.2014.40942","article-title":"Segmental neurofibromatosis","volume":"6","author":"Sobjanek","year":"2014","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/humu.22162","article-title":"Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene","volume":"33","author":"Thomas","year":"2012","journal-title":"Hum. Mutat."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/sj.ejhg.5200493","article-title":"Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene","volume":"8","author":"Tinschert","year":"2000","journal-title":"EJHG"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/humu.20601","article-title":"Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs)","volume":"29","author":"Upadhyaya","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/humu.1380040202","article-title":"Molecular basis of neurofibromatosis type 1 (NF1): mutation analysis and polymorphisms in the NF1 gene","volume":"4","author":"Upadhyaya","year":"1994","journal-title":"Hum. Mutat."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jmoldx.2010.09.002","article-title":"A highly sensitive genetic protocol to detect NF1 mutations","volume":"13","author":"Valero","year":"2011","journal-title":"J. Mol. Diagn."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/cge.12187","article-title":"A clinical and genetic overview of 18 years neurofibromatosis type 1 molecular diagnostics in the Netherlands","volume":"85","author":"Van Minkelen","year":"2014","journal-title":"Clin. Genet."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2164-3-13","article-title":"Complex splicing pattern generates great diversity in human NF1 transcripts","volume":"3","author":"Vandenbroucke","year":"2002","journal-title":"BMC Genomics"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/088307380201700804","article-title":"Genetics of neurofibromatosis 1 and the NF1 gene","volume":"17","author":"Viskochil","year":"2002","journal-title":"J. Child Neurol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/jco.20.02220","article-title":"NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform Neurofibromas","volume":"39","author":"Weiss","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/humu.20493","article-title":"Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5\u2032 splice-site disruption","volume":"28","author":"Wimmer","year":"2007","journal-title":"Hum. Mutat."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1887523\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:56:29Z","timestamp":1786514189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1887523\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":34,"alternative-id":["10.3389\/fnins.2026.1887523"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2026.1887523","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1887523"}}